Caris Life Sciences, Inc. develops and commercializes AI-enabled precision medicine solutions built around comprehensive molecular profiling, next-generation sequencing and machine learning. The company’s diagnostics and data platform use Whole Genome, Whole Exome and Whole Transcriptome Sequencing, a multimodal clinico-genomic database and high-performance computing to support early detection, diagnosis, monitoring, therapy selection and drug development.
Company announcements commonly address molecular profiling services, clinical therapy selection volume, product launches and regulatory or reimbursement actions for tests such as Caris Assure, Caris MI Clarity and Caris ChromoSeq. Other recurring developments include peer-reviewed validation of Caris AI Insights, Caris Precision Oncology Alliance collaborations, conference presentations and quarterly financial results.
Caris Life Sciences (NASDAQ: CAI) will present eight research posters at the ESMO Congress, taking place October 23–27, 2026, in Madrid, Spain.
Two Caris-led studies focus on artificial intelligence models for predicting breast cancer response to capecitabine and assessing risk and potential benefit from extended endocrine therapy. Six collaborative studies with the Caris Precision Oncology Alliance cover lung cancer, endometrial cancer, melanoma and biomarkers related to immunotherapy benefit. The presentations explore molecular profiling and the integration of molecular and clinical data in cancer research.
Caris Life Sciences (CAI) launched a new national advertising campaign, “Math,” featuring actor and filmmaker Kevin Costner to promote early cancer detection and its Caris Detect multi-cancer early detection (MCED) blood test.
The campaign aims to raise awareness that finding cancer earlier may offer more treatment options and better outcomes. Caris Detect is described as a blood test that uses ultra-deep Whole Genome Sequencing, Whole Transcriptome Sequencing and artificial intelligence to analyze molecular signals associated with cancer across the genome and transcriptome, and is now available nationwide.
Caris Life Sciences (CAI) will present seven precision oncology studies at the IASLC 2026 World Conference on Lung Cancer, held September 12-15, 2026, in Seoul, South Korea.
The presentations include two mini oral talks, one Poster Tour and four posters based on large clinico-genomic datasets. Key NSCLC analyses span 39,124 and 43,261 samples, linking MTAP deletion and high PRMT5 expression to shorter overall survival and a less favorable immune microenvironment, and showing race- and ethnicity-related differences in immunotherapy biomarkers, tumor microenvironment and survival. A mesothelioma transcriptomic study of 386 samples defines three biologically distinct clusters, where chemotherapy ± bevacizumab outperformed immune checkpoint inhibitors in two clusters. Additional posters report clinically relevant germline variants in 12.2% of 3,609 NSCLC patients and 13.4% of 149 small cell lung cancer patients, RET+ non-LUAD outcomes, and divergent prognostic impact of ITGB6 expression by NSCLC histology.
Caris Life Sciences (NASDAQ: CAI) reported publication in npj Precision Oncology of a study validating Caris AI Insights for first-line treatment selection in pancreatic cancer. The AI-driven molecular signature used large clinico-genomic datasets to predict benefit from FOLFIRINOX versus gemcitabine plus nab-paclitaxel (gem/nab-p).
In the testing cohort, standard molecular risk patients predicted to benefit from FOLFIRINOX had a median overall survival of 16.0 months on FOLFIRINOX versus 9.9 months on gem/nab-p. About half of study patients had received a different first-line regimen than the model would have recommended, suggesting potential to improve survival and reduce toxicity through biologically informed choices.
The pancreatic AI signature is integrated into the Caris Molecular Tumor Board Report, generated from whole exome and whole transcriptome sequencing via the MI Cancer Seek assay. According to Caris Life Sciences, MI Cancer Seek received FDA approval in November 2024 as the first simultaneous WES/WTS-based assay with companion diagnostic indications for solid tumors.
Caris Life Sciences (Nasdaq: CAI) reported second quarter 2026 revenue of $263.7 million, up 45% year over year, driven mainly by $252.3 million in molecular profiling services revenue. The company completed approximately 59,200 clinical cases, up about 18%, and delivered a gross margin of 68%, roughly 500 bps higher than a year earlier.
Net loss narrowed to $0.6 million, with positive Adjusted EBITDA of $55.7 million, operating cash flow of $28.5 million and free cash flow of $6.4 million. Caris raised its 2026 revenue guidance to $1.03–$1.04 billion, implying 27%–28% growth, and reaffirmed clinical therapy selection volume growth of about 20%. The company also highlighted multiple product launches, MolDX approval for Caris ChromoSeq, a dual listing on NYSE Texas, and an authorized share repurchase program of up to $100 million, with approximately $82.1 million remaining.
Caris Life Sciences (NASDAQ: CAI) will report its second quarter 2026 financial results on Wednesday, August 5, 2026, and will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the results. A replay will be available on the company’s Investor Relations website.
Caris Life Sciences (NASDAQ: CAI) announced it will offer in-house PTEN immunohistochemistry (IHC) testing for metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer, following recent FDA approval of a PTEN biomarker-guided therapy and companion diagnostic assay. The assay is intended to identify PTEN-deficient tumors, which occur in about one in four patients with this disease and are linked to faster progression and poorer outcomes.
According to Caris, PTEN IHC testing will be run in its CAP-accredited, CLIA-certified labs to support faster results, integrate with its multi-platform molecular profiling (including NGS), and expand its broader portfolio of assays such as MI Cancer Seek, Caris Assure, Caris MI Clarity, Caris Chromoseq and Caris Detect.
Caris Life Sciences (NASDAQ: CAI) announced the commercial launch of Caris Detect, a multi-cancer early detection blood test using ultra-deep Whole Genome and Whole Transcriptome sequencing combined with AI.
The test analyzes DNA, RNA and other molecular signals, leveraging a database of over one million cases and 50 billion markers. Data from the Caris Detect ACHIEVE 1 study showed strong performance across multiple cancer types. Caris plans further research and future study milestones to expand capabilities over time.
Caris Life Sciences (NASDAQ: CAI) announced a dual listing of its common stock on NYSE Texas, effective June 17, 2026. Shares will keep trading on NASDAQ and also list on NYSE Texas under the CAI ticker, aiming for greater investor exposure, especially in Texas.
Caris Life Sciences (Nasdaq: CAI) announced that its board authorized a share repurchase program for up to $100 million of outstanding common stock. Repurchases may occur via open market, privately negotiated deals, or Rule 10b5-1 trading plans and will follow Rule 10b-18 requirements.
The program has no expiration date, does not require any minimum repurchases, and can be modified, suspended, or discontinued at any time. Caris currently expects to fund buybacks using available cash and cash equivalents.